Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1981-5-13
|
pubmed:abstractText |
Cytomegalovirus (CMV)-specific immune responses and the general cellular immune status of 24 untreated patients with Hodgkin's disease (HD) and 22 with non-Hodgkin lymphoma (NHL) were evaluated in comparison with matched controls. The incidence of antibodies against CMV-induced early (EA) or late (LA) antigens was not different between patients and controls. LA antibody titres were markedly lower in the lymphoma patients (p = 0.01), especially in the NHL subgroup (p = 0.008), but not in HD patients. EA antibody titre levels were not significantly different between patients and controls. CMV-specific lymphocyte reactivity (LR) was impaired in LA seropositive--and even more so in EA seropositive--lymphoma patients. General cellular immunity tested with LR to mitogens and an antigen cocktail was more disturbed in HD patients (only PWM-LR normal) than in NHL patients (only Con A-LR disturbed). The percentage of circulating T lymphocytes was markedly lowered (less than 60%) in only 2 HD and 4 NHL patients. The impairment of CMV-LR was not directly related to the general cellular immune status of the patients. It appeared furthermore to be virus-specific when it was compared with LR to Epstein-Barr virus antigen. The impairment of CMV-specific immunity in lymphoma patients probably reflects a defect of the immunological defence against endogenous CMV. This defect apparently, occurs early in the course of illness before the general cellular immune status has deteriorated and it may have a pathogenetic significance for lymphoid malignancies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0141-2760
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
145-51
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6259357-Adolescent,
pubmed-meshheading:6259357-Adult,
pubmed-meshheading:6259357-Aged,
pubmed-meshheading:6259357-Antibodies, Viral,
pubmed-meshheading:6259357-Child,
pubmed-meshheading:6259357-Cytomegalovirus,
pubmed-meshheading:6259357-Female,
pubmed-meshheading:6259357-Herpesvirus 4, Human,
pubmed-meshheading:6259357-Hodgkin Disease,
pubmed-meshheading:6259357-Humans,
pubmed-meshheading:6259357-Immunity, Cellular,
pubmed-meshheading:6259357-Leukocyte Count,
pubmed-meshheading:6259357-Lymphocyte Activation,
pubmed-meshheading:6259357-Lymphoma,
pubmed-meshheading:6259357-Male,
pubmed-meshheading:6259357-Middle Aged,
pubmed-meshheading:6259357-T-Lymphocytes
|
pubmed:year |
1980
|
pubmed:articleTitle |
Cytomegalovirus-specific immune response and the cellular immune status of malignant lymphoma.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|